anti-ROR1 antibody scFv conjugates (Oncternal Therapeutics)

N/A

Report date: 2025/03/18 18:09:57

Base Information

Drug Nameanti-ROR1 antibody scFv conjugates (Oncternal Therapeutics)
Drug Alias Nameanti-ROR1 antibody scFv conjugates (University of California San Diego)anti-ROR1 antibody scFv conjugates (Shanghai Pharma Biotherapeutics USA)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesOncternal Therapeutics IncShanghai Pharma Biotherapeutics USA Inc
Inactive CompaniesUniversity Of California San Diego
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A